Plasmodium Immunotherapy for Advanced Ovarian Cancer

Exclusion Criteria

• •Subjects who have any of the following conditions cannot be included in the study:
• •1. Have received any investigational drug within 4 weeks before the first inoculation of Plasmodium parasite, or have participated in another clinical study at the same time (except that the subjects have participated in the observational and non-interventive clinical study, or are in the follow-up period of the intervention clinical study);
• •2. Immunodeficiency diseases, including HIV infection, other acquired and congenital immunodeficiency diseases;
• •3. Coagulation dysfunction, or acute or chronic hemorrhagic disease;
• •4. Have received other anti-tumor treatment in the past, and the period from the termination of treatment to the screening is less than 14 days or 5 half-lives (whichever occurs first);
• •5. The time interval between radiotherapy and treatment in this study for patients who have previously received external or internal radiotherapy is less than 28 days;
• •6. Patients with severe hemoglobinopathy or severe Glucose-6-Phosphate Dehydrogenase(G6PD) deficiency;
• •7. After splenectomy or splenomegaly;
• •8. Drug addicts or alcohol addicts;
• •9. Plenty of pleural effusion, pericardial effusion or ascites;
• •10. Patients with active hepatitis B or hepatitis C;
• •11. Patients with obvious defects in immunocyte classification test (CD4+T cell absolute count\<200/ μ l）； Or receive any form of immunosuppressive treatment within 28 days before the trial treatment;
• •12. Have serious or uncontrolled systemic diseases (including but not limited to active infection, grade III hypertension, unstable angina pectoris, congestive heart failure, grade III or IV heart disease, serious arrhythmia, liver and kidney insufficiency, myocardial infarction, etc.);
• •13. Currently has mental disorder or a history of mental illness;
• •14. Having undergone major surgery within three months from the screening period;
• •15. Have received bone marrow transplantation or organ transplantation in the past;
• •16. Moderate or severe pulmonary ventilation dysfunction;
• •17. Those who are currently receiving regular anti-tumor treatment, and the treatment is effective or there is no obvious progress in the disease;
• •18. The investigator evaluated the patients who could not tolerate Plasmodium immunotherapy;
• •19. Pregnancy, lactation or pregnancy within 6 months after treatment;
• •20. According to the judgment of the researcher, the other conditions of the subject are not suitable for participating in the test.